Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:FULC NASDAQ:NTLA NASDAQ:SNDX NASDAQ:SRPT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFULCFulcrum Therapeutics$6.82+0.6%$7.25$5.88▼$15.74$454.42M3.02898,311 shs313,647 shsNTLAIntellia Therapeutics$13.68+1.8%$13.52$6.83▼$28.25$1.91B1.935.50 million shs4.52 million shsSNDXSyndax Pharmaceuticals$19.75+0.7%$22.40$8.59▼$25.59$1.75B0.411.45 million shs1.02 million shsSRPTSarepta Therapeutics$17.30+3.7%$19.99$10.41▼$43.92$1.83B0.262.92 million shs2.93 million shsDon't wait for the SpaceX IPOThe space race is growing fast, and you don’t have to wait for SpaceX to go public to invest. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFULCFulcrum Therapeutics+0.30%+6.77%-12.18%-22.34%+6.77%NTLAIntellia Therapeutics+6.58%+9.62%+3.27%-5.88%+44.21%SNDXSyndax Pharmaceuticals-1.46%-2.58%-6.62%-5.13%+97.48%SRPTSarepta Therapeutics+0.06%-2.57%-20.50%-4.41%-56.51%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFULCFulcrum Therapeutics$6.82+0.6%$7.25$5.88▼$15.74$454.42M3.02898,311 shs313,647 shsNTLAIntellia Therapeutics$13.68+1.8%$13.52$6.83▼$28.25$1.91B1.935.50 million shs4.52 million shsSNDXSyndax Pharmaceuticals$19.75+0.7%$22.40$8.59▼$25.59$1.75B0.411.45 million shs1.02 million shsSRPTSarepta Therapeutics$17.30+3.7%$19.99$10.41▼$43.92$1.83B0.262.92 million shs2.93 million shsDon't wait for the SpaceX IPOThe space race is growing fast, and you don’t have to wait for SpaceX to go public to invest. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFULCFulcrum Therapeutics+0.30%+6.77%-12.18%-22.34%+6.77%NTLAIntellia Therapeutics+6.58%+9.62%+3.27%-5.88%+44.21%SNDXSyndax Pharmaceuticals-1.46%-2.58%-6.62%-5.13%+97.48%SRPTSarepta Therapeutics+0.06%-2.57%-20.50%-4.41%-56.51%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFULCFulcrum Therapeutics 2.50Moderate Buy$19.00178.59% UpsideNTLAIntellia Therapeutics 2.35Hold$20.2548.03% UpsideSNDXSyndax Pharmaceuticals 2.92Moderate Buy$42.55115.42% UpsideSRPTSarepta Therapeutics 2.11Hold$27.1757.07% UpsideCurrent Analyst Ratings BreakdownLatest FULC, NTLA, SNDX, and SRPT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/26/2026SRPTSarepta Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D+) ➝ Sell (D)5/22/2026SNDXSyndax Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$40.005/13/2026NTLAIntellia Therapeutics Sanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Perform$13.00 ➝ $17.005/13/2026NTLAIntellia Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$30.00 ➝ $25.005/13/2026SNDXSyndax Pharmaceuticals UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$38.00 ➝ $37.005/12/2026NTLAIntellia Therapeutics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$58.00 ➝ $49.005/12/2026NTLAIntellia Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral$12.005/8/2026SRPTSarepta Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D) ➝ Sell (D+)5/1/2026SNDXSyndax Pharmaceuticals BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$35.00 ➝ $37.004/28/2026NTLAIntellia Therapeutics The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetSell$8.00 ➝ $9.004/28/2026NTLAIntellia Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform(Data available from 5/28/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFULCFulcrum Therapeutics$80M5.68N/AN/A$5.00 per share1.36NTLAIntellia Therapeutics$67.67M28.25N/AN/A$4.44 per share3.08SNDXSyndax Pharmaceuticals$172.35M10.15N/AN/A$0.47 per share42.02SRPTSarepta Therapeutics$2.18B0.84N/AN/A$14.26 per share1.21Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFULCFulcrum Therapeutics-$74.88M-$1.15N/AN/AN/AN/A-27.80%-26.32%8/4/2026 (Estimated)NTLAIntellia Therapeutics-$412.69M-$3.54N/AN/AN/A-597.04%-57.47%-46.24%8/6/2026 (Estimated)SNDXSyndax Pharmaceuticals-$285.42M-$2.79N/AN/AN/A-111.88%-256.65%-45.25%8/3/2026 (Estimated)SRPTSarepta Therapeutics-$713.41M-$0.96N/A7.550.19-2.94%7.56%2.94%8/5/2026 (Estimated)Latest FULC, NTLA, SNDX, and SRPT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/11/2026Q1 2026NTLAIntellia Therapeutics-$0.92-$0.81+$0.11-$0.81$13.81 million$15.05 million5/6/2026Q1 2026SRPTSarepta Therapeutics$0.9760$3.16+$2.1840$2.88$474.16 million$730.80 million4/30/2026Q1 2026SNDXSyndax Pharmaceuticals-$0.59-$0.48+$0.11-$0.48$69.76 million$64.86 million4/27/2026Q1 2026FULCFulcrum Therapeutics-$0.31-$0.25+$0.06-$0.25N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthFULCFulcrum TherapeuticsN/AN/AN/AN/AN/ANTLAIntellia TherapeuticsN/AN/AN/AN/AN/ASNDXSyndax PharmaceuticalsN/AN/AN/AN/AN/ASRPTSarepta TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFULCFulcrum TherapeuticsN/A34.3334.33NTLAIntellia TherapeuticsN/A6.106.10SNDXSyndax Pharmaceuticals8.265.475.06SRPTSarepta Therapeutics0.564.632.62Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFULCFulcrum Therapeutics89.83%NTLAIntellia Therapeutics88.77%SNDXSyndax PharmaceuticalsN/ASRPTSarepta Therapeutics86.68%Insider OwnershipCompanyInsider OwnershipFULCFulcrum Therapeutics7.00%NTLAIntellia Therapeutics3.10%SNDXSyndax Pharmaceuticals4.10%SRPTSarepta Therapeutics6.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableFULCFulcrum Therapeutics10066.63 million61.97 millionOptionableNTLAIntellia Therapeutics600139.72 million135.39 millionOptionableSNDXSyndax Pharmaceuticals11088.61 million84.98 millionOptionableSRPTSarepta Therapeutics1,372105.58 million98.29 millionOptionableFULC, NTLA, SNDX, and SRPT HeadlinesRecent News About These CompaniesIn Solid Cash Position, Sarepta Therapeutics Inc (SRPT) Outlines 2026 PrioritiesMay 27 at 6:00 PM | finance.yahoo.comAssessing Sarepta Therapeutics (SRPT) Valuation After Recent Share Price WeaknessMay 26 at 2:49 PM | finance.yahoo.comKROS Stock Guide to Rinvatercept in DMD and ALS for 2026May 22, 2026 | finance.yahoo.comShould You Buy KROS After Q1 Miss and Takeda Deal Reset?May 22, 2026 | finance.yahoo.comKROS Turns to Next Wave of TGF-Beta Muscle TherapiesMay 22, 2026 | finance.yahoo.comWhy Elevidys Matters For Sarepta Therapeutics Inc (SRPT) StockMay 20, 2026 | finance.yahoo.comWhy Elevidys Matters For Sarepta Therapeutics Inc (SRPT) StockMay 20, 2026 | insidermonkey.comImmunic appoints Biogen, Cubist veteran Mike Bonney as board chair ahead of key MS trial readoutMay 19, 2026 | proactiveinvestors.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Zoetis (ZTS), Sarepta Therapeutics (SRPT) and GoodRx Holdings (GDRX)May 17, 2026 | theglobeandmail.comSarepta Therapeutics: Buy Rating Reiterated on Elevidys Uptake Outlook and Microdystrophin Validation; $35 Price Target UnchangedMay 15, 2026 | tipranks.comAnalysts Offer Insights on Healthcare Companies: Arvinas Holding Company (ARVN), Sarepta Therapeutics (SRPT) and Surgery Partners (SGRY)May 14, 2026 | theglobeandmail.comSarepta Therapeutics' (NASDAQ:SRPT) Earnings Are Built On Soft FoundationsMay 14, 2026 | finance.yahoo.comSarepta Therapeutics to Present at the RBC Capital Markets Global Healthcare ConferenceMay 13, 2026 | finance.yahoo.comSarepta Therapeutics to Present at the RBC Capital Markets Global Healthcare ConferenceMay 13, 2026 | businesswire.comSarepta Therapeutics (SRPT) Gets a Buy from OppenheimerMay 12, 2026 | theglobeandmail.comWells Fargo Sticks to Their Buy Rating for Sarepta Therapeutics (SRPT)May 11, 2026 | theglobeandmail.comA Look At Sarepta Therapeutics (SRPT) Valuation After Q1 Profitability Return And Pipeline ProgressMay 9, 2026 | finance.yahoo.comVanguard Group Inc. Grows Stock Holdings in Sarepta Therapeutics, Inc. $SRPTMay 9, 2026 | marketbeat.comSarepta Therapeutics' Commercial Portfolio Alone Should Support Higher Valuation, Wedbush SaysMay 8, 2026 | finance.yahoo.comSarepta (SRPT) Q1 2026 Earnings TranscriptMay 8, 2026 | finance.yahoo.comSRPT stock plunges 7% after-hours as Elevidys demand slumps — CEO still sees return to growthMay 8, 2026 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeFULC, NTLA, SNDX, and SRPT Company DescriptionsFulcrum Therapeutics NASDAQ:FULC$6.82 +0.04 (+0.59%) Closing price 04:00 PM EasternExtended Trading$6.82 +0.00 (+0.07%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Intellia Therapeutics NASDAQ:NTLA$13.68 +0.24 (+1.79%) Closing price 04:00 PM EasternExtended Trading$13.70 +0.02 (+0.15%) As of 05:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.Syndax Pharmaceuticals NASDAQ:SNDX$19.75 +0.14 (+0.71%) As of 04:00 PM EasternSyndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.Sarepta Therapeutics NASDAQ:SRPT$17.30 +0.62 (+3.72%) Closing price 04:00 PM EasternExtended Trading$17.26 -0.05 (-0.26%) As of 05:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Snowflake and the Snowballing Impact of its AI Flywheel IREN Is Flipping the Switch from Bitcoin to AI 3 Stocks Rallying on Micron's Price Boost: Substance or Hype? This Quantum Computing Stock May Be Closer to a Breakout Than You Think Microsoft Is Spending Billions on AI, But Investors Aren’t Buying It AI’s Biggest Bottleneck Could Make These 2 Stocks Soar If the Market Rally Stalls, This ETF Can Insulate Portfolios RTX Is Set to Revolutionize Munitions Manufacturing Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
